Immunology meets bioengineering: Improving the effectiveness of glioblastoma immunotherapy

View/ Open
Date
2022Author
Fekrirad, ZahraBehrooz, Amir Barzegar
Ghaem, Shokoofeh
Khosrojerdi, Arezou
Zarepour, Atefeh
Zarrabi, Ali
Arefian, Ehsan
Ghavami, Saeid
Metadata
Show full item recordCitation
Fekrirad Z, Barzegar Behrooz A, Ghaemi S, Khosrojerdi A, Zarepour A, Zarrabi A, Arefian E, Ghavami S. Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy. Cancers (Basel). 2022 Jul 29;14(15):3698. doi: 10.3390/cancers14153698. PMID: 35954362; PMCID: PMC9367505.Abstract
Glioblastoma (GBM) therapy has seen little change over the past two decades. Surgical excision followed by radiation and chemotherapy is the current gold standard treatment. Immunotherapy techniques have recently transformed many cancer treatments, and GBM is now at the forefront of immunotherapy research. GBM immunotherapy prospects are reviewed here, with an emphasis on immune checkpoint inhibitors and oncolytic viruses. Various forms of nanomaterials to enhance immunotherapy effectiveness are also discussed. For GBM treatment and immunotherapy, we outline the specific properties of nanomaterials. In addition, we provide a short overview of several 3D (bio)printing techniques and their applications in stimulating the GBM microenvironment. Lastly, the susceptibility of GBM cancer cells to the various immunotherapy methods will be addressed.